Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib trial of Atu027 in Combination With Cisplatin, 5FU and Cetuximab in Patients With Head and Neck Cancer

Trial Profile

Phase Ib trial of Atu027 in Combination With Cisplatin, 5FU and Cetuximab in Patients With Head and Neck Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATU 027 (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Acronyms PACiFiC
  • Most Recent Events

    • 02 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per United Kingdom Clinical Research Network.
    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top